Volume 33, Issue 4 (July 2022)                   Studies in Medical Sciences 2022, 33(4): 265-273 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behzadi F, Rastegarnia M, Roosta Y. EVALUATION OF THE INCIDENCE OF RENAL FAILURE AND ITS RELATED RISK FACTORS IN ADMITTED PATIENTS WITH MULTIPLE MYELOMA AT IMAM KHOMEINI UNIVERSITY HOSPITAL, URMIA, IRAN. Studies in Medical Sciences 2022; 33 (4) :265-273
URL: http://umj.umsu.ac.ir/article-1-5723-en.html
Assistant professor, Hematology, Immune Cell Therapy, and Stem Cells Transplantation Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran (Corresponding Author) , yroosta@gmail.com
Abstract:   (1451 Views)
Background & Aims: Multiple myeloma (MM) is defined as a plasma cell dyscrasia, accounting for approximately 10% of all hematologic malignancies. The aim of this study was to evaluate renal failure occurrence in MM patients admitted to Imam Khomeini Hospital in Urmia, Iran.
Materials & Methods: In this cross-sectional study, the files of patients with multiple myeloma were examined from March 2015 to March 2020. Also, the underlying diseases involved in the occurrence of kidney failure along with related risk factors such as hypercalcemia and infection were also investigated. Finally, the study data were analyzed using SPSS version 16.
Results: According to the obtained results, the frequency of renal failure in the patients was 42.2%. The mean age of patients was 63.7±13.10 years, with a higher rate among men. Based on paraclinical assessments, the mean serum hemoglobin level (Hb) was significantly lower in patients with renal failure (P = 0.001). Also, the amount of hypercalcemia was significantly higher in the people with kidney failure (p<0.001). Hypertension was also seen significantly more in the patients with kidney failure as an important risk factor (p=0.01). Pathological fractures in the spine and skull bones were mainly observed in these patients. There was no significant difference in the prevalence of infection, serum levels of gamma globulin, albumin, and plasma cells between patients with and without renal insufficiency.
Conclusion: The results of this study showed that the prevalence of renal failure was higher in the patients with multiple myeloma, and as a result, it can be considered as one of the important tissue-damaging factors with a poor prognosis. Hypertension, anemia, and hypercalcemia were important prognostic factors in the occurrence of this complication.
Full-Text [PDF 460 kb]   (363 Downloads)    
Type of Study: Research | Subject: انکولوژی بالینی

References
1. Kumar SK, Rajkumar V, Kyle RA, Van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat. Rev. Dis. Primers2017;3 (1):1 -.20 [DOI:10.1038/nrdp.2017.46] [PMID]
2. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res2011;183:25 -35. [DOI:10.1007/978-3-540-85772-3_2] [PMID]
3. Ramsenthaler C, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study. Palliat Med2019;33 (5):541 -551. [DOI:10.1177/0269216319833588] [PMID]
4. Sy-Go JPT, Dingli D, Gertz MA, Kapoor P, Buadi FK, Dispenzieri A, et al. Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. Kidney Int Rep2020;6 (3):857 -64. [DOI:10.1016/j.ekir.2020.12.007] [PMID] [PMCID]
5. Mussap M, Merlini G. Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media? Biomed Res Int2014;2014:167125. [DOI:10.1155/2014/167125] [PMID] [PMCID]
6. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia2008;22 (8):1485 -93. [DOI:10.1038/leu.2008.131] [PMID]
7. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med2009;150 (9):604 -12. [DOI:10.7326/0003-4819-150-9-200905050-00006] [PMID] [PMCID]
8. Yong Z-h, Yu X-j, Lin Z-s, Zhou F-d, Cen X-n, Wang S-x, et al. Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report. BMC Nephrology2021;22 (1):1 -7. [DOI:10.1186/s12882-020-02204-x] [PMID] [PMCID]
9. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology2004;231 (1):11 -23. [DOI:10.1148/radiol.2311020452] [PMID]
10. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med2004;128 (8):875 -9. [DOI:10.5858/2004-128-875-RPSIAA] [PMID]
11. Montseny J-J, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant1998;13 (6):1438 -45. [DOI:10.1093/ndt/13.6.1438] [PMID]
12. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol2012;8 (1):43 -51. [DOI:10.1038/nrneph.2011.168] [PMID] [PMCID]
13. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol2014;15 (12):e538-e48. [DOI:10.1016/S1470-2045(14)70442-5] [PMID]
14. Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management. Am J Hematol2014;89 (10):998 -1009. [DOI:10.1002/ajh.23810] [PMID]
15. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer 2004;101(11):2667-74. [DOI:10.1002/cncr.20652] [PMID]
16. de Freitas Ferreira HH, Silva ASJ, Júnior Jr LSDS, de Medeiros Oliveira GH, Araujo MdGP, lima Soares V, et al. Multiple Myeloma Course with Renal Insufficiency in Young Patient: Case Report. Blood2020;136:26. [DOI:10.1182/blood-2020-143302]
17. Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J2021;11 (2):1 -6. [DOI:10.1038/s41408-021-00408-4] [PMID] [PMCID]
18. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al., editors. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;78 (1):21 -33. [DOI:10.4065/78.1.21] [PMID]
19. Almueilo SH. Renal failure in patients with multiple myeloma. Saudi J Kidney Dis Transpl2015;26 (3):482 -8. [DOI:10.4103/1319-2442.157327] [PMID]
20. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma2007;48 (2):337 -41. [DOI:10.1080/10428190601126602] [PMID]
21. Mussap M, Merlini G. Pathogenesis of renal failure in multiple myeloma: any role of contrast media? Biomed Res Int2014;2014. Article ID167125. [DOI:10.1155/2014/167125] [PMID] [PMCID]
22. Khalil SH, Padmos MA, Ernst P, Clink HM. Multiple myeloma: a review of 92 cases at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Ann Saudi Med1991;11 (6):642 -6. [DOI:10.5144/0256-4947.1991.642] [PMID]
23. Moustapha M, Guillaume M, Fall K, Tall A, Faye A. Prognostic Factors of Renal Impairment in Multiple Myeloma in Senegal. J Nephrol Urol2018;2 (1):12. [URL]
24. Elmira M, Bahareh M, Mohammad A. Cancer and kidney new concepts and views. Med J Tabriz Uni Med Sci2015;37 (1): 6-13. [Google Scholar]
25. Chu P. Managing multiple myeloma patients with renal failure. Hong Kong J Nephrol2013;15 (2):62 -7. [DOI:10.1016/j.hkjn.2013.09.001]
26. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol2016;34 (13):1544 -57. [DOI:10.1200/JCO.2015.65.0044] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb